Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062803) FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062803 International Application No.: PCT/CN2018/107899
Publication Date: 04.04.2019 International Filing Date: 27.09.2018
IPC:
C07D 417/02 (2006.01) ,C07D 417/10 (2006.01) ,A61K 31/41 (2006.01) ,A61K 31/00 (2006.01) ,A61P 25/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
10
linked by a carbon chain containing aromatic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
Applicants:
基石药业 CSTONE PHARMACEUTICALS [GB/GB]; 开曼群岛大开曼岛西湾路802号芙蓉路格兰德展厅邮政信箱编号31119 P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman KY1-1205, KY
基石药业(苏州)有限公司 CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD. [CN/CN]; 中国江苏省苏州市 苏州工业园区星湖街218号生物纳米园A1楼北座二楼E168单元 Building A1 E168, 218 Xinghu St., Suzhou Industrial Park Suzhou, Jiangsu 215123, CN
拓石药业(上海)有限公司 CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD. [CN/CN]; 中国上海市 自由贸易试验区德堡路38号1幢2层211-20室 Room 211-20, Building 1, 38 Debao Rd., Pilot Free Trade Zone Shanghai 200000, CN
南京明德新药研发股份有限公司 MEDSHINE DISCOVERY INC. [CN/CN]; 中国江苏省南京市 南京高新开发区高新路9号商务办公楼218室 Room 218, No.9 Gaoxin Road, Gaoxin Development District Nanjing, Jiangsu 210032, CN
Inventors:
陈新海 CHEN, Kevin X.; CN
周凯 ZHOU, Kai; CN
胡伯羽 HU, Boyu; CN
肖敏亮 XIAO, Minliang; CN
陈曙辉 CHEN, Shuhui; CN
Agent:
上海弼兴律师事务所 SHANGHAI BESHINING LAW OFFICE; 中国上海市 小木桥路681号外经大厦21楼 21st Floor, SFECO Mansion, 681 Xiaomuqiao Road Shanghai 200032, CN
Priority Data:
201710900542.828.09.2017CN
201810239824.221.03.2018CN
Title (EN) FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR
(FR) DÉRIVÉ À CYCLE FUSIONNÉ UTILISÉ EN TANT QU'INHIBITEUR DU RÉCEPTEUR A2A
(ZH) 作为A2A受体抑制剂的并环类衍生物
Abstract:
(EN) Disclosed are a compound represented by formula (I) or a pharmaceutically-acceptable salt thereof, and an application of the compound or salt in preparation of drugs for treating diseases related to an A2A receptor.
(FR) L'invention concerne un composé représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, et une application du composé ou du sel dans la préparation de médicaments pour le traitement de maladies liées à un récepteur A2A.
(ZH) 公开了式(I)所示化合物或其药学上可接受的盐,并涉及其在制备治疗与A2A受体相关疾病药物中的应用。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)